Replies to post #128017 on Biotech Values

[biomaven0]

One interesting point in the MNTA patent litigation might be the distinction between potentially infringing on the patents while developing the product and infringing on the patent when actually manufacturing the product.

I wonder if the loophole that allows a company to infringe on a patent for the purposes of R&D prior to FDA approval (meant to apply to a composition of matter patent) might apply here?

Peter